- Details
- Treatment options in metastatic castration-resistant prostate cancer (mCRPC) who have soft-tissue progression after second-generation anti-androgen therapies are limited. Single-agent studies of cabozantinib, a tyrosine kinase inhibitor (TKI) that regulates cell growth, angiogenesis, and immune cell regulation, and the anti-PD-L1 antibody atezolizumab each showed limited efficacy as monotherapy. (...
|
- Details
- Tanya Dorff joins Alicia Morgans discussing recent updates to the NCCN guidelines for systemic therapies in the treatment of M1 prostate cancer. The CARD trial was a multicenter, randomized, open-label study that enrolled men with metastatic castration-resistant prostate cancer (mCRPC) between 2015 and 2018. Patients were eligible if they had evidence of symptomatic progressive disease within 12 m...
|
- Details
- Treatments in advanced prostate cancer continued to progress from research into clinical practice throughout 2020. Alicia Morgans, MD, MPH, and Charles Ryan, MD, discuss trials that matured, new drugs that were approved, and novel molecular imaging that transformed the prostate cancer treatment continuum. Biographies: Charles J. Ryan, MD , the President and Chief Executive Officer of The Prostate...
|
- Details
- 68 Ga-PSMA-11, the first drug for PET imaging of prostate-specific membrane antigen (PSMA)–positive lesions in men with prostate cancer (PC), was approved on December 1, 2020, by the United States Federal Drug Administration (FDA). Joining Phillip Koo is Johannes Czernin, one of the original pioneers who started the process of getting gallium-68 PSMA approved in the United States. Dr. Czernin deta...
|
- Details
- Medical Oncologist, Ben Tran, MBBS, FRACP, joins Alicia Morgans, MD, MPH, Oliver Sartor, MD, and Neal Shore, MD, FACS to speak about the first in-human study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific t-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) designed to understand the effects of BiTE AMG 160 and prostate cancer cells....
|
- Details
- AMG 160 is a half-life extended (HLE) BiTE® molecule designed to engage the patient’s own T cells with PSMA on prostate cancer cells, activating the cytotoxic potential of T cells to eliminate cancer. In this conversation with Alicia Morgans, MD, MPH, Medical Oncologist, Researcher, and co-investigator on the first in human, interim results of a phase 1 study of AMG 160, Tanya Dorff, MD from the C...
|
- Details
- In the CARD study, cabazitaxel significantly improved radiographic progression-free survival and overall survival versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and the alternative androgen signaling-targeted inhibitor. Here, we report the quality-of-life outcomes from the CARD study. In the quality-of-life anal...
|
- Details
- In this conversation with Alicia Morgans, MD, MPH, Ben Tran, MBBS, FRACP, highlights the interim results from a phase 1 study of AMG160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) presented at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress. Biographies: Ben Tran, MBB...
|
- Details
- Alicia Morgans, MD, MPH presents a State of Art Lecture on treatment selection for mCRPC patients who have disease progression progressing after combination treatment for in metastatic castration-sensitive prostate cancer (mCSPC). The learning objectives of this presentation include to understand the rationale for avoiding sequencing of androgen receptor-targeted agents one after another, how to c...
|
- Details
- Thomas Keane highlights the PROfound Study, Olaparib for Metastatic Castrate Resistant Prostate Cancer , published in the New England Journal of Medicine this year. The study found that in men with metastatic prostate cancer with genetic alterations relating to homologous recombination repair who have shown disease progression while receiving ezalutamide or abiraterone, olaparib was associated wit...
|
